PhysioGenix Names Dr. Magdalena Alonso-Galicia as Senior Study Director

Dr. Alonso-Galicia brings eight years of experience at Merck to PhysioGenix, expands cardiovascular and metabolic preclinical research expertise.

Milwaukee, WI (PRWEB) November 13, 2009 -- PhysioGenix, Inc., a world-leader in research services and solutions in the fields of chronic disease, today announced that Dr. Magdalena Alonso-Galicia joined the Company. Dr. Alonso-Galicia has over thirteen years of research experience in renal and cardiovascular physiology. Prior to joining PhysioGenix, she spent eight years as Senior Research Pharmacologist and as a Research Fellow at Merck. She will work directly with clients who are working to discover cures for such diseases as diabetes, obesity and hypertension, to develop customized research programs. “We are very pleased to have Dr. Alonso join us. She is a great addition to our team and will be key in achieving our goal of becoming a world-leader in chronic disease research services and solutions.” says Dr. Brian Curry, CEO of PhysioGenix.

Dr. Alonso-Galicia holds a combined degree in chemistry, biology, and pharmacy from the University of San Luis Potosi, a doctoral degree in Physiology & Biophysics from the University of Mississippi, and a postdoctoral fellowship from the Medical College of Wisconsin. Her passion for helping others through research of obesity-induced hypertension will be a valuable asset for PhysioGenix.

About PhysioGenix

Healthcare trends. The United States has witnessed a dramatic change in the disease profile that contributes to morbidity and mortality. Today “chronic disease” defined by the CDC are non-communicable illnesses that are prolonged in duration, do not resolve spontaneously, and are rarely cured completely such as heart disease, cancer, and diabetes, which are the most prevalent and costly health issues. Every year chronic diseases cause 7 out of 10 deaths in the United States. This corresponds to 133 million Americans or nearly 1 in 2 adults living with a chronic disease. Chronic diseases also place a heavy burden on the United States healthcare system representing over 75% of all healthcare costs.

A world-leader in chronic disease research services and solutions. Our goal is to be the world-leader in research services for organizations conducting studies involving therapeutics and medical devices for chronic diseases. Through our in-house capabilities and partnerships with outside experts, we seek to deliver the most comprehensive suite of solutions in our fields of expertise.

Our services. We provide a full range of drug research services. From study design to reporting, our clients have come to appreciate our time sensitive, client focused services. Our capabilities include bioanalytical services, safety pharmacology, pharmacokinetics, drug metabolism, pharmacodynamics, phenotyping and specialized blood pressure monitoring.

###